EN ENGGY 로딩 중... : 애널리스트의 강세 및 약세 의견

Zimmer Biomet is executing a multi-year overhaul of its entire US sales channel, moving from a largely non-dedicated (1099) and non-specialized model to a fully dedicated and specialized one. The company states current productivity is roughly half of direct competitors, and that the transition could take through 2027 to complete. — This deliberate sales disruption in the US is a direct driver of the company's lowered 2026 guidance, signaling a potential near-term share shift in the large-joints market as competitors (Stryker, Enovis, Smith+Nephew) may capitalize on the disruption.